Medical Doctor Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Leland Dennis

Psychiatry Guthrie, OK Medical Doctor

NPI 1033155197 CMS profile 183186

5201 Ne Highway 33, Guthrie, OK 73044

Open in the dashboard

General payments

$3,194

150 records reported · program years 2020–2023

Research payments

$1,556

Paid to them · 7 records reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Leland Dennis of Guthrie, OK is reported in the CMS Open Payments database as having received $3,194 across 150 general payments and $1,556 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $2,185 51
2022 General $627 60
2021 General $382 39
2020 Research $1,556 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leland Dennis
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Leland Dennis were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Leland Dennis Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $382 $143 $43–$576 $132
2022 $627 $153 $50–$590 $149
2023 $2,185 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. Alkermes, Inc. $1,081 13 payments
  2. Janssen Pharmaceuticals, Inc $786 33 payments
  3. AbbVie, Inc. $482 63 payments
  4. Otsuka America Pharmaceutical, Inc. $147 8 payments
  5. Teva Pharmaceuticals USA, Inc. $143 9 payments
  6. Lundbeck LLC $132 6 payments
  7. ITI, Inc. $108 1 payment
  8. Indivior Inc. $98 6 payments
  9. Vanda Pharmaceuticals Inc. $82 4 payments
  10. Neurocrine Biosciences, Inc. $64 3 payments
  11. Other $72 4 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $2,394 149 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $800 1 payment
Products named General payments · program years 2020–2023
  1. LYBALVI Cns $1,081 13 payments
  2. LYBALVI Cns $851 3 payments
  3. LYBALVI Cns $829 2 payments
  4. LYBALVI Cns $829 2 payments
  5. INVEGA SUSTENNA $626 29 payments
  6. VRAYLAR $482 63 payments
  7. ARISTADA Cns $252 11 payments
  8. ARISTADA Cns $252 11 payments
  9. ARISTADA Cns $230 10 payments
  10. ARISTADA Cns $230 10 payments
  11. Other $1,153 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2023
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,556 7 payments

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record